Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Update

Aldeyra Therapeutics, Inc (NASDAQ:ALDX - Get Free Report) was the target of a significant decline in short interest in November. As of November 30th, there was short interest totalling 3,410,000 shares, a decline of 12.3% from the November 15th total of 3,890,000 shares. Based on an average daily trading volume, of 476,600 shares, the days-to-cover ratio is presently 7.2 days.

Institutional Investors Weigh In On Aldeyra Therapeutics

Institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC grew its position in Aldeyra Therapeutics by 7.9% during the second quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company's stock valued at $30,703,000 after acquiring an additional 682,265 shares during the period. Federated Hermes Inc. acquired a new position in shares of Aldeyra Therapeutics in the 2nd quarter valued at about $1,758,000. PFG Investments LLC purchased a new stake in shares of Aldeyra Therapeutics during the 2nd quarter worth about $1,312,000. Jacobs Levy Equity Management Inc. increased its position in Aldeyra Therapeutics by 163.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company's stock worth $2,571,000 after purchasing an additional 295,864 shares in the last quarter. Finally, International Assets Investment Management LLC raised its holdings in Aldeyra Therapeutics by 397.0% in the third quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company's stock valued at $15,480,000 after buying an additional 229,487 shares during the period. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Price Performance

ALDX traded down $0.11 during trading on Friday, hitting $4.90. The company's stock had a trading volume of 303,196 shares, compared to its average volume of 493,708. Aldeyra Therapeutics has a twelve month low of $2.71 and a twelve month high of $6.55. The firm's 50 day moving average price is $5.15 and its 200-day moving average price is $4.74. The company has a current ratio of 6.80, a quick ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX - Get Free Report) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, hitting the consensus estimate of ($0.25). As a group, equities research analysts anticipate that Aldeyra Therapeutics will post -0.92 earnings per share for the current year.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company's lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.